Abstract:Activation of the toll-like receptors 7 and 8 has emerged as a promising strategy for cancer immunotherapy. Herein, we report the design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds 24e and 25a significantly induced the secretion of IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10 in human peripheral blood mononuclear cell assays. In vivo, compounds 24e, 24m, and 25a significantly suppressed tumor growth in CT26 tumor-bearing mice by remodeling the tumor microenvironment. Additionally, compounds 24e, 24m, and 25a markedly improved the antitumor activity of PD-1/PD-L1 blockade. In particular, compound 24e combined with the anti-PD-L1 antibody led to complete tumor regression. These results demonstrated that TLR7/8 agonists (24e, 24m, and 25a) held great potential as single agents or in combination with PD-1/PD-L1 blockade for cancer immunotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00179?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00179</a>.Homology and similarity analysis between TLR7 and 8; agonistic activities of compounds 24e, 25a, and 26a in other homologous TLRs; supplementary multiplexed immunoassays for cytokines; synergy analysis of tumor size and the survival rate; representative flow cytometric analysis of tumor-infiltrating immune cells; detection of absolute counts of tumor-infiltrating immune cells and synergy analysis; relationships between the TVs and the amounts of immune cells; phospholipidosis detection of 24e, 24m, and 25a; synthesis of compounds 16a, 27, and 35; NMR spectra of target compounds; and HPLC traces of compounds 5, 24e, 24k, 24m, 25a, and 34 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_002.csv">CSV</a>)Molecular docking for GS-9620 into TLR7 and molecular docking for 17d, 24e, 24m, and 34, into TLR7 and TLR8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia

Design, synthesis and biological evaluation of marine naphthoquinone-naphthol derivatives as potential anticancer agents

Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Design, synthesis and antitumor activity of triphenylphosphonium-linked derivatives of quinazolinone

Design, synthesis and biological evaluation of quinazoline and pyrrolo[3,2- d ]pyrimidine derivatives as TLR7 agonists for antiviral agents

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology

Design and Optimisation of a Small-Molecule TLR2/4 Antagonist for Anti-Tumour Therapy.

Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition

Design, Synthesis, and Structure–Activity Relationship of N -Aryl- N ′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy

Design, Synthesis and Anticancer Activity of Naphthoquinone Derivatives.

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

Synthesis, Biological Evaluation, and Molecular Docking Studies of 2,6-Dinitro-4-(trifluoromethyl)phenoxysalicylaldoxime Derivatives As Novel Antitubulin Agents.

Design, synthesis, and evaluation of proliferation inhibitory activity of novel L-shaped ortho-quinone analogs as anticancer agents

Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA

Molecular Mechanisms of Chemotherapy-Induced Hair Loss

Structure-based design, synthesis and biological evaluation of N-substituted 6H-thiochromeno[2,3–c]quinolin-12(12H)-ones as potential breast cancer drugs

Design, Synthesis and Biological Evaluation of a Series of New Resveratrol Analogues As Potential Anti-Cancer Agents

Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives As Novel Inhibitors of VEGFR2.